Purple biotech to participate in the h.c. wainwright 27th annual global investment conference

Rehovot, israel, aug. 27, 2025 (globe newswire) -- purple biotech ltd. (“purple biotech” or “the company”) (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the company's ceo, gil efron will participate in a fireside chat and 1x1 investor meeting at the h.c. wainwright 27th annual global investment conference, being held september 8-10, 2025.
PPBT Ratings Summary
PPBT Quant Ranking